

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549

DIVISION OF CORPORATION FINANCE

March 7, 2013

<u>Via E-mail</u> Ms. Liat Sossover Chief Financial Officer Brainstorm Cell Therapeutics, Inc. 605 Third Avenue, 34th Floor New York, New York 10158

> Re: Brainstorm Cell Therapeutics, Inc. Preliminary Proxy Statement on Schedule 14A Filed on March 4, 2013 File No. 000-54365

Dear Ms. Sossover:

We have limited our review of your preliminary proxy statement to the issue we have addressed in our comment. Please respond to this letter by revising the proxy statement. Where you do not believe our comment applies to your facts and circumstances, please tell us why in your response.

After reviewing the information you provide in response to our comment, we may have additional comments.

1. We note that the reverse stock split will result in an increase in the number of shares the Company has available for issuance. Please revise your disclosure to describe any specific plans, arrangements or understandings, whether written or oral, to issue any of the shares that will be newly available following the reverse stock split. If you have no such plans, arrangement or understandings, please revise your disclosure to so state.

We urge all persons who are responsible for the accuracy and adequacy of the disclosure in the filing to be certain that the filing includes the information the Securities Exchange Act of 1934 and all applicable Exchange Act rules require. Since the company and its management are in possession of all facts relating to a company's disclosure, they are responsible for the accuracy and adequacy of the disclosures they have made.

In responding to our comment, please provide a written statement from the company acknowledging that:

- the company is responsible for the adequacy and accuracy of the disclosure in the filing;
- staff comments or changes to disclosure in response to staff comments do not foreclose the Commission from taking any action with respect to the filing; and

Liat Sossover Brainstorm Cell Therapeutics, Inc. March 7, 2013 Page 2

• the company may not assert staff comments as a defense in any proceeding initiated by the Commission or any person under the federal securities laws of the United States.

You may contact Johnny Gharib at (202) 551-3170, Daniel Greenspan at (202) 551-3623 or me at (202) 551-3715 with any questions.

Sincerely,

/s/ Daniel Greenspan for

Jeffrey P. Riedler Assistant Director

cc: <u>Via E-mail</u> Thomas B. Rosedale, Esq. BRL Law Group LLC 425 Boylston Street, 3rd Floor Boston, Massachusetts 02116